Calcium dobesilate: possibility of therapy of chronic venous disease

Cover Page

Cite item

Full Text

Abstract

In a review article devoted to phlebotropic therapy in the treatment of patients with chronic venous insufficiency of the lower extremities are considered one of the drugs of this group - calcium dobesilate. Analysis of domestic and foreign literature indicates the effectiveness of its use in patients of this category, as evidenced by a number of international studies and the inclusion of the drug in the Russian clinical practice guidelines for the diagnosis and treatment of chronic venous diseases. The mechanism of action, providing anti-edematous, anti-inflammatory, antithrombotic effects, allows to use it not only in phlebology. Multimedialne action of calcium dobesilate allows its use both as a vasoprotector in patients with diabetic retinopathy and nephropathy.

About the authors

Yu. M Stoiko

N.I.Pirogov National Medical and Surgical Center of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., зав. каф. хирургии с курсами травматологии, ортопедии и хирургической эндокринологии Института усовершенствования врачей ФГБУ «Национальный медико-хирургический центр им. Н.И.Пирогова» 105203, Russian Federation, Moscow, ul. Nizhniaia Pervomaiskaia, d. 70

V. G Gudymovich

N.I.Pirogov National Medical and Surgical Center of the Ministry of Health of the Russian Federation

Email: gudvic@mail.ru
д-р. мед. наук, доцент каф. хирургии с курсами травматологии, ортопедии и хирургической эндокринологии Института усовершенствования врачей ФГБУ «Национальный медико-хирургический центр им. Н.И.Пирогова» 105203, Russian Federation, Moscow, ul. Nizhniaia Pervomaiskaia, d. 70

References

  1. Клиническая флебология. Под ред. Ю.Л.Шевченко, Ю.М.Стойко. М.: ДПК Пресс, 2016.
  2. Совещание экспертов. Российские клинические рекомендации по диагностике и лечению хронических заболеваний вен, основанные на принципах доказательной медицины. Рабочие материалы. М., 2008.
  3. Rabe E, Guex J.J, Puskas A et al. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol 2012; 31 (2): 105-15.
  4. Nicolaides A, Kakkos S, Eklof B et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Int Angiol 2014; 33 (2): 126-39.
  5. Garay R.P, Hannaert P, Chiavaroli C. Calcium dobesilate in the treatment of diabetic retinopathy. Treat Endocrinol 2005; 4 (4): 221-32.
  6. Mestres P, Rodriguez L, Erill S, Laport J. Modification by calcium dobesilate of histamine effects on capillary ultra - structure. Experientia 1975; 31: 826-9.
  7. Zabel-Langhennig R, Kulle M. Capillary fragility in diabetics and its modification by calcium dobesilate. Z Gesamte Inn Med 1983; 38: 633-6.
  8. Van Bijsterveld O.P, Janssen P.T. The effect of calcium dobe - silate on albumin leakage of the conjunctival vessels. Curr Eve Res 1981; 1: 425-30.
  9. Allain H, Ramelet A.A, Polard E, Bentué-Ferrer D. Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids. Drug Saf 2004; 27: 649-60.
  10. Demirtas S, Caliskan A, Guclu O et al. Can calcium dobesilate be used safely for peripheral microvasculopathies that require neoangiogenesis? Med Sci Monit Basic Res 2013; 19: 253-7.
  11. Alda O, Valero M.S, Pereboom D et al. In vitro calcium dobesilate on oxidative/inflammatory stress in hunan varicosae veins. Phlebology 2011; 26 (8): 332-7.
  12. Angulo J, Peiró C, Romacho T et al. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate. Eur J Pharmacol 2011; 667: 153-9.
  13. Brunet J, Farine J.C, Garay R.P, Hannaert P. In vitro antioxidant properties of calcium dobesilate. Fundam Clin Pharmacol 1998; 12: 205-12.
  14. Piller N.B. The lymphagogue action of calcium dobesilate on the flow of lymph from the thoracic duct of anesthetized and mobile guinea pigs. Lymphology 1988; 21: 124-7.
  15. Flota-Cervera F, Flota-Ruiz C, Treviño C, Berber A. Randomized, double blind, placebo - controlled clinical trial to evaluate the lymphagogue effect and clinical efficacy of calcium dobesilate in chronic venous disease. Angiology 2008; 59 (3): 352-6.
  16. Ciapponi A, Laffaire E, Roqué M. Calcium dobesilate for chronic venous insufficiency: a systematic review. Angiology 2004; 55 (2): 147-54.
  17. Martinez-Zapata M.J, Vernooij R.W, Uriona Tuma S.M et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev 2016; 4: CD003229.
  18. Российские клинические рекомендации по диагностике и лечению хронических заболеваний вен. Флебология. 2013; 7 (2): 2-48.
  19. Cai T, Wu X.Y, Zhang X.Q et al. Calcium Dobesilate Prevents Diabetic Kidney Disease by Decreasing Bim and Inhibiting Apoptosis of Renal Proximal Tubular Epithelial Cells. DNA Cell Biol 2017; 36 (4): 249-55.
  20. Rabe E.L, Jaeger K.A, Bulitta M, Pannier F. Calcium dobesilate in patients suffering from chronic venous insufficiency: a double - blind, placebo - controlled, clinical trial. Phlebology 2016; 26 (4): 162-8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).